Huasun(SZ:000790)2023-04-27 16:00Financial Performance - The company's revenue for Q1 2023 was CNY 220,289,718.39, representing a 6.40% increase compared to CNY 206,595,617.51 in the same period last year[5]. - Net profit attributable to shareholders decreased by 63.00% to CNY 3,209,240.40 from CNY 9,433,788.66 year-on-year[5]. - The total operating revenue for Q1 2023 was CNY 220,289,718.39, an increase of 6.04% compared to CNY 207,039,241.91 in Q1 2022[21]. - The net profit for Q1 2023 was CNY 3,098,819.01, a decrease of 56.5% from CNY 7,132,012.43 in Q1 2022[22]. - The basic and diluted earnings per share for Q1 2023 were both CNY 0.0051, down from CNY 0.0139 in Q1 2022, reflecting a decline in profitability per share[23]. Cash Flow - The cash flow from operating activities showed a significant decline of 645.24%, resulting in a net outflow of CNY 119,963,874.13 compared to a net inflow of CNY 19,660,473.69 in the previous year[5]. - Cash inflow from operating activities totaled 140,610,550.26, down from 227,591,626.13, representing a decrease of approximately 38.3%[24]. - Cash outflow from operating activities increased to 260,574,424.39 from 205,589,514.05, marking an increase of about 26.7%[24]. - The net cash flow from operating activities was -119,963,874.13, a significant decline compared to 22,002,112.08 in the previous period[24]. - The net cash flow from investing activities was -41,959,403.22, an improvement from -193,328,707.98 in the previous period[25]. - Total cash inflow from financing activities reached 263,834,018.63, a substantial increase from 28,020,000.00[25]. - The net cash flow from financing activities was 228,454,523.64, compared to 27,659,959.66 previously, indicating a significant increase[25]. Assets and Liabilities - Total assets increased by 15.91% to CNY 1,943,849,980.16 from CNY 1,677,058,446.16 at the end of the previous year[5]. - The total current assets increased to ¥1,028,022,488.01 from ¥784,306,279.15, reflecting a growth of 31.1%[17]. - The total liabilities rose to CNY 900,538,882.81 in Q1 2023, up from CNY 671,561,352.92 in Q1 2022, indicating an increase of 34.06%[19]. - The company's long-term investments increased to CNY 55,604,898.43 in Q1 2023, compared to CNY 14,519,833.30 in Q1 2022, showing a strategic focus on long-term growth[19]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 47,722[12]. - The largest shareholder, Sichuan Huashen Group, holds 111,431,281 shares, accounting for 17.74% of total shares[12]. - The company has 269,460 restricted stocks released for trading as of January 3, 2023, following the first phase of its stock incentive plan[14]. - The company repurchased and canceled 431,000 restricted stocks due to the departure of four incentive plan participants[14]. Operational Changes - The company completed a controlling acquisition of Shandong Lingkai Pharmaceutical Co., Ltd., increasing its stake from 49% to 70%[15]. - The company plans to establish Shandong Lingkai as a CDMO and synthetic biology production base, enhancing its competitive edge in the industry[15]. Other Financial Metrics - The weighted average return on equity decreased to 0.32% from 0.96% in the previous year[5]. - The company's cash and cash equivalents increased to ¥244,209,509.01 from ¥144,637,734.98 at the beginning of the year, representing a growth of 68.9%[17]. - Accounts receivable decreased slightly to ¥410,957,042.61 from ¥412,729,958.09, showing a decrease of 0.4%[17]. - The company has a total of 54,109,956.51 in other receivables, up from 28,123,081.88, indicating a growth of 92.6%[17]. - The company's cash outflow from investing activities decreased by 76.28% to CNY 46,911,431.72, mainly due to reduced payments for investments in new subsidiaries[11]. - The company reported a cash inflow of 4,952,028.50 from investment activities, slightly up from 4,466,000.00[25].